- ACOG committee opinion: tamoxifen and endometrial cancer. Number 232, April 2000. Committee on Gynecological Practice, the American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2001;73:77-79.
- ACOG committee opinion: tamoxifen and uterine cancer. Number 336, June 2006. Committee on Gynecological Practice, the American College of Obstetricians and Gynecologists. Obstet Gynecol 2006;107(6):1475-1478.
- Aziz S, Kuperstein G, Rosen B, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001;80:341-345.
- Boike G, Averette H, Hoskins W, et al. National survey of ovarian carcinoma. IV. Women with prior hysterectomy: a failure of prevention? Gynecol Oncol 1993;A22:112.
- Bourne TH, Campbell S, Reynolds KM, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ 1993;306:1025-1029.
- Boyd J. BRCA: the breast, ovarian, and other cancer genes. Gynecol Oncol 2001;80:337-340.
- Chalas E, Costantino JP, Wickerham DL, et al. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol 2005;192:1230-1237.
- Cohen I, Beyth Y, Tepper R. The role of ultrasound in the detection of endometrial pathologies in asymptomatic postmenopausal breast cancer patients with tamoxifen treatment. Obstet Gynecol Surv 1998;53:429-438.
- Cohen I, Rosen DJ, Tepper R, et al. Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med 1993;12:275-280.
- Exacoustos C, Zupi E, Cangi B, et al. Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound, color flow Doppler, hysteroscopic and histological study. Ultrasound Obstet Gynecol 1995;6:435-442.
- Fisher B, Costantino JP, Wickerham L, et al. Tamoxifen for prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 2005;97:1652-1662.
- Ford D, Easton DF, Bishop DT, et al. Risk of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-695.
- Goldstein SR, Scheele WH, Rajagopalan SK, et al. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 2000;95:95-103.
- Ismail SM. Gynecological effects of tamoxifen. J Clin Pathol 1999;52:83-88.
- Jaiyesimi IA, Buzdar AU, Decker DA, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995;13:513-529.
- Jishi MF, Itnyre JH, Oakley-Girvan IA, et al. Risks of cancer among members of families in the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1995;76:1416-1421.
- Kauff ND, Mitra N, Robson ME, et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. J Natl Cancer Inst 2005;97:1382-1384.
- Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2742-2751.
- Levine MF, Argenta PA, Yee CJ, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 2003;21:4222-4227.
- Miller SM, Fang CY, Manne SL, et al. Decision making about prophylactic oophorectomy among at-risk women: psychological influences and implications. Gynecol Oncol 1999;75:406-412.
- Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:235-240.
- Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-428.
- Pepper JM, Oyesanya OA, Dewart PJ, et al. Indices of differential endometrial: myometrial growth may be used to improve the reliability of detecting endometrial neoplasia in women on tamoxifen. Ultrasound Obstet Gynecol 1996;8:408-411.
- Piver MS, Jishi MF, Tsukada Y, et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: a report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993;71:2751-2755.
- Prat J, Ribe A, Gallardo A. Hereditary ovarian cancer. Hum Pathol 2005;36:861-870.
- The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987;316:650-655.
- Struewing JP, Watson P, Easton DF, et al. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 1995;17:33-35.
- Tepper R, Cohen I, Altaras M, et al. Doppler flow evaluation of pathologic endometrial conditions in postmenopausal breast cancer patients treated with tamoxifen. J Ultrasound Med 1994;13:635-640.
- Tobacman JK, Greene MH, Tucker MA, et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982;2:795-797.
Health.am